- Home
- HCA vs ZTS Comparison
HCA vs ZTS Comparison
Compare HCA & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCA
- ZTS
- Stock Information
- Founded
- HCA 1968
- ZTS 1952
- Country
- HCA United States
- ZTS United States
- Employees
- HCA N/A
- ZTS N/A
- Industry
- HCA Hospital/Nursing Management
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- HCA Health Care
- ZTS Health Care
- Exchange
- HCA Nasdaq
- ZTS Nasdaq
- Market Cap
- HCA 76.9B
- ZTS 80.4B
- IPO Year
- HCA N/A
- ZTS 2013
- Fundamental
- Price
- HCA $310.54
- ZTS $165.86
- Analyst Decision
- HCA Buy
- ZTS Strong Buy
- Analyst Count
- HCA 15
- ZTS 8
- Target Price
- HCA $383.36
- ZTS $215.38
- AVG Volume (30 Days)
- HCA 1.3M
- ZTS 2.7M
- Earning Date
- HCA 01-24-2025
- ZTS 02-13-2025
- Dividend Yield
- HCA 0.85%
- ZTS 1.04%
- EPS Growth
- HCA 9.31
- ZTS 8.38
- EPS
- HCA 22.31
- ZTS 5.32
- Revenue
- HCA $69,621,000,000.00
- ZTS $9,152,000,000.00
- Revenue This Year
- HCA $9.58
- ZTS $9.48
- Revenue Next Year
- HCA $6.05
- ZTS $4.87
- P/E Ratio
- HCA $13.92
- ZTS $31.20
- Revenue Growth
- HCA 10.23
- ZTS 9.33
- 52 Week Low
- HCA $278.68
- ZTS $144.80
- 52 Week High
- HCA $417.14
- ZTS $200.53
- Technical
- Relative Strength Index (RSI)
- HCA 50.36
- ZTS 46.04
- Support Level
- HCA $300.16
- ZTS $161.58
- Resistance Level
- HCA $314.50
- ZTS $169.78
- Average True Range (ATR)
- HCA 7.12
- ZTS 3.56
- MACD
- HCA 2.51
- ZTS 0.84
- Stochastic Oscillator
- HCA 83.85
- ZTS 57.34
About HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.